ContraFect Corp.
(NASDAQ : CFRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.06%333.400.0%$4450.25m
BNTXBioNTech SE 2.54%269.520.0%$741.56m
NVAXNovavax, Inc. -15.21%136.1379.4%$602.92m
AMGNAmgen, Inc. 1.42%209.721.4%$554.08m
SNSSSunesis Pharmaceuticals, Inc. 4.81%6.440.7%$450.18m
REGNRegeneron Pharmaceuticals, Inc. 1.72%561.592.7%$438.99m
GILDGilead Sciences, Inc. 0.29%67.101.0%$414.29m
CCXIChemoCentryx, Inc. 3.45%34.812.9%$398.63m
ILMNIllumina, Inc. -0.16%413.443.3%$374.04m
XLRNAcceleron Pharma, Inc. -0.56%172.765.3%$348.35m
VRTXVertex Pharmaceuticals, Inc. 0.45%186.241.9%$270.97m
BIIBBiogen, Inc. -0.43%266.981.7%$242.49m
OCGNOcugen, Inc. 6.42%8.870.0%$187.85m
XENEXenon Pharmaceuticals, Inc. 2.21%30.470.4%$163.92m
CRSPCRISPR Therapeutics AG -1.64%98.610.6%$159.45m

Company Profile

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.